Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients

Journal of Autoimmunity

Volumn 50, Issue , 2014, Pages 135-141

  Calich, Ana Luisa ^a,b   Puéchal, Xavier ^a,c   Pugnet, Grégory ^a,d   London, Jonathan ^a   Terrier, Benjamin ^a,c   Charles, Pierre ^a   Mouthon, Luc ^a,c   Guillevin, Loïc ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c CNRS   (France)

^d CHU PURPAN   (France)

Author keywords

ANCA associated vasculitis; Glucocorticoids; Granulomatosis with polyangiitis; Maintenance; Remission induction treatment; Rituximab

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RITUXIMAB; GLUCOCORTICOID; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ABDOMINAL INFECTION; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INFUSION; DRUG PULSE THERAPY; DRUG SAFETY; DRUG THERAPY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRANULOMATOSIS WITH POLYANGIITIS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION PREVENTION; LEUKOCYTE DISORDER; LONG TERM CARE; LOW DRUG DOSE; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEUTROPENIA; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; RECURRENT DISEASE; REMISSION; REMISSION INDUCTION THERAPY; RETROSPECTIVE STUDY; SKIN INFECTION; SUBGLOTTIC STENOSIS; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERINE CERVIX CANCER; WEGENER GRANULOMATOSIS; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG MONITORING; IMMUNOLOGY; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; GRANULOMATOSIS WITH POLYANGIITIS; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PREDNISONE; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84899116092     PISSN: 08968411     EISSN: 10959157     Source Type: Journal    
DOI: 10.1016/j.jaut.2014.03.002     Document Type: Article

References (47)

1. Jennette J.C., Falk R.J., Bacon P.A., Basu N., Cid M.C., Ferrario F., et al. 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Arthritis Rheum 2013, 65:1-11.
2. Fauci A.S., Wolff S.M. Wegener's granulomatosis: studies in eighteen patients and a review of the literature. Medicine (Baltimore) 1973, 52:535-561.
3. Fauci A.S., Haynes B.F., Katz P., Wolff S.M. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983, 98:76-85.
4. Hoffman G.S., Kerr G.S., Leavitt R.Y., Hallahan C.W., Lebovics R.S., Travis W.D., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 1992, 116:488-498.
5. Charlier C., Henegar C., Launay O., Pagnoux C., Berezné A., Bienvenu B., et al. Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 2009, 68:658-663.
6. Langford C.A. Cyclophosphamide as induction therapy for Wegener's granulomatosis and microscopic polyangiitis: cyclophosphamide as induction therapy. Clin Exp Immunol 2011, 164:31-34.
7. Guillevin L. L51. From immunosuppression to selective treatments: the benefit-risk ratio. Presse Med 2013, 42:641-643.
8. Specks U., Fervenza F.C., McDonald T.J., Hogan M.C. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum 2001, 44:2836-2840.
9. Jones R.B., Tervaert J.W.C., Hauser T., Luqmani R., Morgan M.D., Peh C.A., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. NEngl J Med 2010, 363:211-220.
10. Stone J.H., Merkel P.A., Spiera R., Seo P., Langford C.A., Hoffman G.S., et al. Rituximab versus cyclophosphamide for ANCA-associated vasculitis. NEngl J Med 2010, 363:221-232.
11. Keogh K.A., Wylam M.E., Stone J.H., Specks U. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:262-268.
12. Keogh K.A., Ytterberg S.R., Fervenza F.C., Carlson K.A., Schroeder D.R., Specks U. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am J Respir Crit Care Med 2006, 173:180-187.
13. Jones R.B., Ferraro A.J., Chaudhry A.N., Brogan P., Salama A.D., Smith K.G.C., et al. Amulticenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2009, 60:2156-2168.
14. Rhee E.P., Laliberte K.A., Niles J.L. Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis. Clin J Am Soc Nephrol 2010, 5:1394-1400.
15. Cartin-Ceba R., Golbin J.M., Keogh K.A., Peikert T., Sánchez-Menéndez M., Ytterberg S.R., et al. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center. Arthritis Rheum 2012, 64:3770-3778.
16. Holle J.U., Dubrau C., Herlyn K., Heller M., Ambrosch P., Noelle B., et al. Rituximab for refractory granulomatosis with polyangiitis (Wegener's granulomatosis): comparison of efficacy in granulomatous versus vasculitic manifestations. Ann Rheum Dis 2012, 71:327-333.
17. Specks U., Merkel P.A., Seo P., Spiera R., Langford C.A., Hoffman G.S., et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. NEngl J Med 2013, 369:417-427.
18. Smith R.M., Jones R.B., Guerry M.-J., Laurino S., Catapano F., Chaudhry A., et al. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2012, 64:3760-3769.
19. Besada E., Koldingsnes W., Nossent J.C. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre. Rheumatology (Oxford) 2013, 52:2041-2047.
20. Charles P., Néel A., Tieulié N., Hot A., Pugnet G., Decaux O., et al. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients. Rheumatology (Oxford) 2014, 53:532-539.
21. Charles P., Guillevin L. S3. Rituximab for ANCA-associated vasculitides: the French experience. Presse Med 2013, 42:534-536.
22. Leavitt R.Y., Fauci A.S., Bloch D.A., Michel B.A., Hunder G.G., Arend W.P., et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990, 33:1101-1107.
23. Damoiseaux J., Dähnrich C., Rosemann A., Probst C., Komorowski L., Stegeman C.A., et al. Anovel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis 2009, 68:228-233.
24. Mukhtyar C., Lee R., Brown D., Carruthers D., Dasgupta B., Dubey S., et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3). Ann Rheum Dis 2009, 68:1827-1832.
25. Exley A.R., Bacon P.A., Luqmani R.A., Kitas G.D., Carruthers D.M., Moots R. Examination of disease severity in systemic vasculitis from the novel perspective ofdamage using the vasculitis damage index (VDI). Br J Rheumatol 1998, 37:57-63.
26. Hellmich B., Flossmann O., Gross W.L., Bacon P., Willem Cohen-Tervaert J., Guillevin L., et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 2007, 66:605-617.
27. Hoffman G.S., Drucker Y., Cotch M.F., Locker G.A., Easley K., Kwoh K. Wegener's granulomatosis: patient-reported effects of disease on health, function, and income. Arthritis Rheum 1998, 41:2257-2262.
28. Condon M.B., Ashby D., Pepper R.J., Cook H.T., Levy J.B., Griffith M., et al. Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids. Ann Rheum Dis 2013, 72:1280-1286.
29. Ooka S., Maeda A., Ito H., Omata M., Yamada H., Ozaki S. Treatment of refractory retrobulbar granuloma with rituximab in a patient with ANCA-negative Wegener's granulomatosis: a case report. Mod Rheumatol 2009, 19:80-83.
30. Thiel J., Hässler F., Salzer U., Voll R.E., Venhoff N. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome). Arthritis Res Ther 2013, 15:R133.
31. Aries P.M., Hellmich B., Voswinkel J., Both M., Nölle B., Holl-Ulrich K., et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis 2006, 65:853-858.
32. Malm I.-J., Mener D.J., Kim J., Seo P., Kim Y.J. Otolaryngological progression of granulomatosis with polyangiitis after systemic treatment with rituximab. Otolaryngol Head Neck Surg 2014, 150:68-72.
33. Hoffman G.S. L52. Vasculitis treatment: is it time to change the standard of care for ANCA-associated vasculitis?. Presse Med 2013, 42:643-650.
34. Venhoff N., Effelsberg N.M., Salzer U., Warnatz K., Peter H.H., Lebrecht D., et al. Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PloS One 2012, 7:e37626.
35. Isvy A., Meunier M., Gobeaux-Chenevier C., Maury E., Wipff J., Job-Deslandre C., et al. Safety of rituximab in rheumatoid arthritis: a long-term prospective single-center study of gammaglobulin concentrations and infections. Jt Bone Spine 2012, 79:365-369.
36. Gottenberg J.-E., Ravaud P., Bardin T., Cacoub P., Cantagrel A., Combe B., et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 2010, 62:2625-2632.
37. Bredemeier M., de Oliveira F.K., Rocha C.M. Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 2014, 66:228-235.
38. Thai L.-H., Charles P., Resche-Rigon M., Desseaux K., Guillevin L. Are anti-proteinase-3 ANCA a useful marker of granulomatosis with polyangiitis (Wegener's) relapses? Results of a retrospective study on 126 patients. Autoimmun Rev 2014, 13:313-318.
39. Miloslavsky E.M., Specks U., Merkel P.A., Seo P., Spiera R., Langford C.A., et al. Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2013, 65:2441-2449.
40. Dass S., Rawstron A.C., Vital E.M., Henshaw K., McGonagle D., Emery P. Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum 2008, 58:2993-2999.
41. Vital E.M., Dass S., Rawstron A.C., Buch M.H., Goëb V., Henshaw K., et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. Arthritis Rheum 2010, 62:1273-1279.
42. Little M.A., Nightingale P., Verburgh C.A., Hauser T., De Groot K., Savage C., et al. Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010, 69:1036-1043.
43. Lund F.E., Hollifield M., Schuer K., Lines J.L., Randall T.D., Garvy B.A. Bcells are required for generation of protective effector and memory CD4 cells in response to pneumocystis lung infection. JImmunol 2006, 176:6147-6154.
44. Martin-Garrido I., Carmona E.M., Specks U., Limper A.H. Pneumocystis pneumonia in patients treated with rituximab. Chest 2013, 144:258-265.
45. Charles P., Bienvenu B., Bonnotte B., Gobert P., Godmer P., Hachulla É., et al. Rituximab: recommendations of the French Vasculitis Study Group (FVSG) for induction and maintenance treatments of adult, antineutrophil cytoplasm antibody-associated necrotizing vasculitides. Presse Med 2013, 42:1317-1330.
46. Specks U. Biologic agents in the treatment of granulomatosis with polyangiitis. Cleve Clin J Med 2012, 79(Suppl.3):S50-S53.
47. Besada E. Routine pneumocystis pneumonia prophylaxis in patients treated with rituximab?. Chest 2013, 144:359-360.